Mylan Laboratories Limited (MLL) has been selected as a leading supplier of antiretroviral (ARV) drugs to India’s National AIDS Control Organisation (NACO).
MLL, with manufacturing units in Hyderabad, is the India subsidiary of US-based Mylan Inc. Naco, part of the Union Ministry of Health and Family Welfare, manages 35 HIV prevention and control societies and 350 ARV treatment centres across the country.
Approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product.
The company has recently entered the Indian commercial market, starting with a portfolio of ARV drugs. Its range of products includes active pharmaceutical ingredients and 43 first- and second-line finished doses, nine of which are paediatric products, a company release said. The Chief Executive Officer of Mylan, Heather Bresch said only through access to these vital medicines can we stem the tide of HIV/AIDS in India and around the world.
The company has a portfolio of more than 1,100 generic pharmaceuticals and several brand medications. It acquired the Hyderabad-based Mylan Laboratories a few years ago.